Cell electrotransfection reagent and application thereof
By treating immune cells with cholesterol derivatives and reducing agents before electroporation and adding reducing agents after electroporation, the problems of low survival rate and exogenous gene expression rate of immune effector cells after electroporation were solved, and a significant improvement in cell survival rate and gene expression was achieved.
Patent Information
- Application Number
- CN202511353237.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-09-20
- Filing Date
- 2025-09-22
- Publication Date
- 2026-03-20
AI Technical Summary
Existing electroporation methods for introducing exogenous genes into immune effector cells such as T cells and TILs suffer from problems such as excessive cell death and low positive rates of exogenous gene expression, especially due to cell membrane perforation and immune response caused by transient high voltage.
Before electroporation, cells were treated with cholesterol derivatives such as cholesterol sulfate and reducing agents such as reduced glutathione, followed by electroporation. The reducing agent was added during the continued culture process after electroporation to improve cell survival rate and positive expression rate of exogenous genes.
It significantly improved the survival rate of immune cells after electroporation and the proportion of cells expressing exogenous genes, and reduced the impact on the immune response.